Metabolites with SARS-CoV-2 Inhibitory Activity Identified from Human Microbiome Commensals

mSphere

Frank J. Piscotta¹  Sean F. Brady¹  Bimal Koirala¹  Seth A. Darst²  Elizabeth A. Campbell²  Gabriel I. Small²  Young Joo Choi²  Charles M. Rice³  Hans-Heinrich Hoffmann³  Alison W. Ashbrook³ 

[1] Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, New York, USA;Laboratory of Molecular Biophysics, The Rockefeller University, New York, New York, USA;Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA;

关键词: biochemistry;    molecular biology;    virology;   

DOI  :  10.1128/mSphere.00711-21

来源: DOAJ

【 摘 要 】

ABSTRACT The COVID-19 pandemic has highlighted the need to identify additional antiviral small molecules to complement existing therapies. Although increasing evidence suggests that metabolites produced by the human microbiome have diverse biological activities, their antiviral properties remain poorly explored. Using a cell-based SARS-CoV-2 infection assay, we screened culture broth extracts from a collection of phylogenetically diverse human-associated bacteria for the production of small molecules with antiviral activity. Bioassay-guided fractionation uncovered three bacterial metabolites capable of inhibiting SARS-CoV-2 infection. This included the nucleoside analogue N6-(Δ2-isopentenyl)adenosine, the 5-hydroxytryptamine receptor agonist tryptamine, and the pyrazine 2,5-bis(3-indolylmethyl)pyrazine. The most potent of these, N6-(Δ2-isopentenyl)adenosine, had a 50% inhibitory concentration (IC50) of 2 μM. These natural antiviral compounds exhibit structural and functional similarities to synthetic drugs that have been clinically examined for use against COVID-19. Our discovery of structurally diverse metabolites with anti-SARS-CoV-2 activity from screening a small fraction of the bacteria reported to be associated with the human microbiome suggests that continued exploration of phylogenetically diverse human-associated bacteria is likely to uncover additional small molecules that inhibit SARS-CoV-2 as well as other viral infections. IMPORTANCE The continued prevalence of COVID-19 and the emergence of new variants has once again put the spotlight on the need for the identification of SARS-CoV-2 antivirals. The human microbiome produces an array of small molecules with bioactivities (e.g., host receptor ligands), but its ability to produce antiviral small molecules is relatively underexplored. Here, using a cell-based screening platform, we describe the isolation of three microbiome-derived metabolites that are able to prevent SARS-CoV-2 infection in vitro. These molecules display structural similarities to synthetic drugs that have been explored for the treatment of COVID-19, and these results suggest that the microbiome may be a fruitful source of the discovery of small molecules with antiviral activities.

【 授权许可】

Unknown